Neurologic Manifestations of Long COVID Differ Based on Acute COVID-19 Severity
Ann Neurol 94:146-159, Giraldo,G.S.P.,et al, 2023
Management of Patients Receiving Interferon Beta-1b for MS:Report of a Consensus Conf
Neurol 46:12-18, Lublin,F.D.,et al, 1996
The COVID-19 Pandemic and the Ethical Duties of the Neurologist
Neurol 95:167-172, Rubin, M.A.,et al, 2020
Interferon beta for Secondary Progressive Multiple Sclerosis: A Systematic Review
JNNP 84:420-426, La Mantia, L.,et al, 2013
Long-Term Survival with Favorable Cognitive Outcome After Chemotherapy in Primary Central Nervous System Lymphoma
Ann Neurol 67:182-189, Juergens,A.,et al, 2010
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Recent Developments in Bell's Palsy
BMJ 329:553-557, Holland,N.J. & Weiner,G.M., 2004
HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Impact of Interferon Beta-1A On Neurologic Disability in Relapsing Multiple Sclerosis
Neurol 49:358-363, Rudick,R.A.,et al, 1997
The Quality-of-Life Effects of Interferon Beta-1b in MS
Arch Neurol 54:1475-1480, Schwartz,C.E.,et al, 1997
Neurologic Manifestations of HIV Infection
Ann Int Med 121:769-785, Simpson,D.M.&Tagliati,M., 1994